Table 2.
Distribution and statistical analysis of resistant GBS strains during the 5-year study period
| Total no. | Pen-R | Amp-R | Cef-R | Van-R | Lev-R | Cli-R | Ery-R | Total no. R* | |
|---|---|---|---|---|---|---|---|---|---|
| 2015 | 550 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 8 (1.4%) | 120 (21.8%) | 138 (25.1%) | 266 (48.3%) |
| 2016 | 648 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 20 (3.1%) | 130 (20.1%) | 143 (22.1%) | 293 (45.3%) |
| 2017 | 700 | 1 (0.1%) | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) | 35 (5.0%) | 270 (38.6%) | 378 (54.0%) | 685 (97.8%) |
| 2018 | 750 | 2 (0.3%)** | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) | 38 (5.1%) | 260 (34.7%) | 337 (44.9%) | 638 (85.1%) |
| 2019 | 846 | 3 (0.3%)*** | 3 (0.3%) | 0 (0.0%) | 0 (0.0%) | 60 (7.1%) | 310 (36.6%) | 406 (48.0%) | 782 (92.3%) |
| 5 years | 3494 | 6 (0.2%) | 5 (0.1%) | 0 (0.0%) | 0 (0.0%) | 161 (4.6%) | 1090 (31.2%) | 1402 (40.1%) | 2664 (76.2%) |
| p Value | 2.12E–14 | 2.26E–01 | 1.99E–01 | – | – | 9.00E–07 | 2.20E–16 | 2.20E–16 | 2.20E–16 |
| χ2 | 70.14 | 5.67 | 6.00 | – | – | 48.10 | 138.90 | 241.30 | 422.33 |
Pen-R penicillin-resistant, Amp-R ampicillin-resistant, Cef-R cefditoren-resistant, Van-R vancomycin-resistant, Lev-R levofloxacin-resistant, Cli-R clindamycin-resistant, Ery-R erythromycin-resistant. *Many strains were multidrug-resistant. **One strain with reduced penicillin susceptibility (PRGBS). ***One strain resistant to both macrolides and fluoroquinolones (multidrug-resistant)